Stock listing
OTC:BGMD BG Medicine Inc Stock
Follow BG Medicine Inc into a list and get an email when it puts out news.
Share price · OTC:BGMD
$0.0001 USD 0.0000 (0.0%)
Close on Nov 5, 2026
- Day range
- $0.0001 – $0.0001 USDNov 5, 2026
- Market cap
- $1,137 USDAt the close on Nov 5, 2026 · price × 11.37M shares outstanding
- 52-week range
- $0.0001 – $0.0001 USDLowest and highest trades, Nov 6, 2025 – Nov 5, 2026
- Traded on an average day
- $0 USDMedian day 0 shares · 64 days with no trades · last 3 months, Aug 5, 2026 – Nov 5, 2026

Daily closes
Last 3 months, Aug 5, 2026 – Nov 5, 2026 · OTC:BGMD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 5,170 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 12,675 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 |
Splits
1 split · OTC:BGMD · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-4 | Consolidation |
- Ticker
- OTC:BGMD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- OTC
- Currency
- USD
Latest news
BG Medicine Inc on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 6 in all · newest Dec 23, 2015 · oldest 2015
- Decks
- 1 deck · latest Feb 13, 2012
Valuation
price Nov 5, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- 0.00
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BG Medicine Inc · OTC:BGMD | US$1,137 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.00 |
| Qlife Holding AB · OMXSTO:QLIFE | US$2.49M | US$2.88M | n/a | 34.1× | n/a | 9.6× | n/a | 3.1× | n/a |
| Physiomics PLC · LSE:PYC | US$2.46M | US$1.91M | n/a | 1.6× | n/a | 3.6× | −74.1% | 0.0× | n/a |
| 20/20 BioLabs, Inc. · NASDAQ:AIDX | US$2.10M | −US$1.01M | n/a | −0.5× | n/a | 3.4× | −317.8% | 0.9× | 1.41 |
| Bluejay Diagnostics, Inc. · NASDAQ:BJDX | US$1.90M | −US$5.43M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.71 |
| Accustem Sciences Inc · OTC:ACUT | US$1.90M | US$1.88M | n/a | n/a | n/a | n/a | n/a | n/a | 0.19 |
| InVitro International · OTC:IVRO | US$1.87M | US$644,260 | 29.6× | 0.8× | 14.0× | 1.1× | 8.2% | 0.0× | 0.17 |
| Co-Diagnostics, Inc. · NASDAQ:CODX | US$1.36M | US$2.21M | n/a | 2.6× | n/a | 0.1× | n/a | 0.2× | 2.16 |
| Prostatype Genomics AB · OMXSTO:PROGEN | US$1.36M | US$1.32M | n/a | 13.3× | n/a | 2.1× | n/a | 0.0× | n/a |
| Virax Biolabs Group Limited · NASDAQ:VRAX | US$446,402 | −US$5.66M | n/a | −455× | n/a | 0.1× | n/a | 0.1× | 1.38 |
| Oxurion NV · EURONEXT:OXUR | US$254,615 | US$12.85M | n/a | 21.1× | n/a | n/a | −671.7% | n/a | n/a |
| Median of the others | US$1.88M | US$1.60M | 29.6× | 2.1× | 14.0× | 1.6× | −195.9% | 0.0× | 1.40 |
Team and board
Officers
| Officer | Role |
|---|---|
| Paul R. Sohmer | Director, President and CEO |
| Charles H. Abdalian | Executive Vice President and CFO |
| Aram Adourian | Senior Vice President and Chief Scientific Officer |
| Carol A. Adiletto | Vice President, Clinical and Regulatory Affairs |
| Howard Rosen | Vice President, Sales and Marketing |
| Stacie Rader | Senior Vice President, Executive Operations & Human Resources |
| Thomas B. Mortensen | Vice President, Sales - Europe |
| Stéphane Bancel | Executive Chairman of the Board |
Board
| Director | Role |
|---|---|
| Stéphane Bancel | Executive Chairman of the Board |
| Brian S. Posner | Director |
| Harrison M. Bains | Director |
| Noubar Afeyan | Director |
| Paul R. Sohmer | Director, President and CEO |
| Stelios Papadopoulos | Director |
| Timothy Harris | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2024 | Nov 19, 2024 | 0.0% |
| Quarter to Jun 30, 2024 | Aug 19, 2024 | |
| Quarter to Mar 31, 2024 | May 16, 2024 | |
| Quarter to Dec 31, 2023 | Feb 28, 2024 | |
| Quarter to Sep 30, 2023 | Nov 14, 2023 | |
| Quarter to Jun 30, 2023 | Aug 14, 2023 | |
| Quarter to Mar 31, 2023 | May 11, 2023 | |
| Quarter to Dec 31, 2022 | Mar 1, 2023 | |
| Quarter to Sep 30, 2022 | Nov 15, 2022 | +50.0% |
| Quarter to Jun 30, 2022 | Aug 15, 2022 |
All 16 quarters
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2022 | May 12, 2022 | |
| Quarter to Dec 31, 2021 | Mar 2, 2022 | |
| Quarter to Sep 30, 2021 | Nov 16, 2021 | |
| Quarter to Jun 30, 2021 | Aug 16, 2021 | |
| Quarter to Mar 31, 2021 | May 13, 2021 | |
| Quarter to Dec 31, 2020 | Mar 3, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (February 2012) | Investor deck | 35 slides | Feb 13, 2012 |
Financials
Annual, in USD
Income statement
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.57M | 2.79M | 4.07M | 2.81M | 1.63M | 819.0K | ||||
| Cost of revenue | 505.0K | 956.0K | 1.39M | 957.0K | 619.0K | 786.0K | ||||
| Gross profit | 1.06M | 1.83M | 2.68M | 1.86M | 1.01M | 33.0K | ||||
| Research and development | 1.77M | 2.39M | 3.73M | 7.58M | 8.00M | 6.54M | ||||
| Selling, general and administrative | 3.62M | 4.51M | 7.13M | 7.55M | 10.5M | |||||
| Operating income | -4.63M | -7.36M | -14.4M | -22.7M | -17.5M | -14.6M | ||||
| Depreciation and amortization | 228.5K | 236.6K | 206.3K | 171.9K | 87.0K | 131.0K | 165.0K | 273.0K | 420.0K | 540.0K |
| EBITDA | -4.54M | -7.23M | -14.2M | -22.5M | -17.1M | -14.1M | ||||
| Interest expense | 159.0K | 728.0K | 1.17M | 1.08M | 89.0K | 2.79M | ||||
| Income before tax | -5.30M | -8.06M | -15.8M | -23.8M | -17.5M | -14.4M | ||||
| Income tax | 159.0K | 597.0K | 1.00M | 810.0K | -323.0K | 2.56M | ||||
| Net income | -5.30M | -8.06M | -15.8M | -23.8M | -17.6M | -17.2M | ||||
| Earnings per share, basic | -0.55 | -0.99 | -2.33 | -4.70 | -3.99 | -23.10 |
Balance sheet
| Line | FY2022 | FY2021 | FY2020 | FY2019 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.52M | 4.12M | 7.75M | 12.8M | 23.9M | 2.42M | ||||
| Short-term investments | 390.0K | 565.0K | ||||||||
| Receivables | 181.0K | 174.0K | 319.0K | 395.0K | 115.0K | 786.0K | ||||
| Inventory | 145.0K | 400.0K | 459.0K | 447.0K | 212.0K | |||||
| Current assets | 1.95M | 4.85M | 8.84M | 14.6M | 25.3M | 3.62M | ||||
| Property, plant and equipment | 11.0K | 117.0K | 192.0K | 197.0K | 301.0K | 604.0K | ||||
| Total assets | 2.13M | 5.23M | 9.35M | 15.2M | 26.1M | 7.03M | ||||
| Accounts payable | 558.0K | 695.0K | 965.0K | 1.11M | 487.0K | 1.38M | ||||
| Current liabilities | 1.18M | 4.58M | 7.35M | 8.31M | 5.20M | 12.1M | ||||
| Long-term debt | 2.96M | 6.61M | ||||||||
| Total debt | 2.96M | 7.31M | 9.86M | 96.0K | ||||||
| Total liabilities | 4.11M | 4.67M | 10.4M | 14.9M | 5.22M | 84.4M | ||||
| Shareholders' equity | -1.98M | 557.0K | -1.07M | 309.0K | 20.9M | -77.4M | ||||
| Shares outstanding | 9.61M | 9.61M | 9.61M | 9.61M | 9.61M | 8.18M | 6.80M | 5.05M | 4.41M | 742.9K |
Cash flow
| Line | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|
| Cash from operations | -3.67M | -8.17M | -15.3M | -21.3M | -15.0M | -11.4M |
| Capital spending | 0 | 0 | -132.0K | -85.0K | -93.0K | -77.0K |
| Free cash flow | -3.67M | -8.17M | -15.4M | -21.4M | -15.1M | -11.5M |
| Cash from investing | 13.0K | 13.0K | -32.0K | -85.0K | -93.0K | 1.98M |
| Cash from financing | 1.06M | 4.54M | 10.3M | 10.3M | 36.5M | 3.52M |
| Dividends paid | -2.50M | |||||
| Share buybacks | -456.0K | 9.02M | 13.1M | 586.0K | 36.6M | |
| Change in cash | -2.60M | -3.63M | -5.04M | -11.1M | 21.4M | -5.92M |
Cap table
Built by 6ix from BG Medicine Inc’s releases
- Common shares
- 11,374,360
- Fully diluted
- 11,374,360
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 11,374,360 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 11,374,360 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Stelios Papadopoulos Other companies: Ovid Therapeutics Inc. (Director, Member of the Audit and Compensation Committees · Since at least Mar 1, 2025); Regulus Therapeutics Inc (Director · Since at least Oct 4, 2012); Exelixis, Inc. (Chair of the Board, Exelixis, Inc. · Since at least May 24, 2012); Eucrates Biomedical Acquisition Corp. (Director · Oct 23, 2020 – Nov 24, 2020 · Past); Biogen Inc. (Director · Jun 8, 2012 – Jun 15, 2022 · Past) | Director · Since at least Nov 9, 2011 |
| Harrison M Bains Jr Other companies: Tvardi Therapeutics, Inc. (Director · Jul 16, 2014 – Jun 1, 2023 · Past) | Director · Jun 12, 2013 – Jun 3, 2014 · Past |
| Anastasia Rader | SVP, Executive Operations & HR · Apr 26, 2013 – Feb 4, 2014 · Past |
| Aram Adourian | Senior Vice President and Chief Scientific Officer · Since at least Nov 4, 2026 |
| Brian S. Posner | Director · Since at least Nov 5, 2026 |
| Carol A. Adiletto | Vice President, Clinical and Regulatory Affairs · Since at least Nov 4, 2026 |
| Charles H. Abdalian | Executive Vice President and CFO · Since at least Nov 5, 2026 |
| Eric Bouvier | President, CEO, Director · Jan 9, 2012 – May 23, 2012 · Past |
| Harrison M. Bains | Director · Since at least Nov 5, 2026 |
| Howard Rosen | Vice President, Sales and Marketing · Since at least Nov 4, 2026 |
All 16 people
| Person | Seat |
|---|---|
| Noubar Afeyan | Director · Since at least Nov 5, 2026 |
| Paul R. Sohmer | Director, President and CEO · Since at least May 8, 2013 |
| Stacie Rader | Senior Vice President, Executive Operations & Human Resources · Since at least Nov 4, 2026 |
| Stéphane Bancel | Executive Chairman of the Board · Since at least Nov 5, 2026 |
| Thomas B. Mortensen | Vice President, Sales - Europe · Since at least Nov 4, 2026 |
| Timothy Harris | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about BG Medicine Inc.